RET Inhibitor is named as a drug or biological intervention in 3 clinical trials in our China, UK and USA trial registers, 3 of which are recruiting. Lead sponsors include BioNTech SE (1), Fujian Medical University (1) and Fudan University (1). Registered phases: Observational and Phase 1. Conditions studied include Thyroid Cancer; Non-Small Cell Lung Cancer; Thyroid Neoplasms.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05142189 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer |
Phase 1 | Recruiting |
| NCT06530316 | RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer (ClinicalTrials.gov ↗) Thyroid Cancer |
Observational | Recruiting |
| NCT07419932 | Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer (ClinicalTrials.gov ↗) Thyroid Cancer, Thyroid Neoplasms |
Observational | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Thyroid Cancer | 2 |
| Non-Small Cell Lung Cancer | 1 |
| Thyroid Neoplasms | 1 |
| Lead sponsor | Trials |
|---|---|
| BioNTech SE | 1 |
| Fujian Medical University | 1 |
| Fudan University | 1 |
| Register | RET Inhibitor trials |
|---|---|
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RET Inhibitor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RET Inhibitor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.